해외 바이오의약품 임상 현황 ('24년 2월 3주)

한국바이오의약품협회, 2024.02.20.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.02.12.~2024.02.18.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 16건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06219174	Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)	Drug: Pembrolizumab|Drug: Difluoromethylornithine	H. Lee Moffitt Cancer Center and Research Institute	Phase 1|Phase 2	
NCT06227026	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies	Biological: Anti-CD19 CAR-T cells	University of Utah	Phase 1	
NCT06218914	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation	Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D	Neogene Therapeutics, Inc.	Phase 1	
NCT05952934	Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence	Biological: 0.5 mL Candin ®/injection|Other: Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)	University of Arkansas	Phase 2	
NCT05805371	PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer	Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Procedure: Biopsy|Procedure: Biospecimen Collection|Procedure: Bone Scan|Procedure: Computed Tomography|Radiation: External Beam Radiation Therapy|Procedure: Leukapheresis|Procedure: Lymphodepletion Therapy	City of Hope Medical Center|National Cancer Institute (NCI)	Phase 1	
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy|Procedure: Biospecimen Collection|Procedure: Computed Tomography|Biological: Pembrolizumab|Drug: Propranolol|Other: Questionnaire Administration	Roswell Park Cancer Institute	Phase 2	
NCT05655949	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	Drug: Gemcitabine|Drug: Cisplatin|Drug: Durvalumab|Radiation: Yttrium-90	Beth Israel Deaconess Medical Center|AstraZeneca|Sirtex Medical|Dana-Farber Cancer Institute	Phase 2	
NCT05518032	Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)	Procedure: Biopsy|Biological: Pembrolizumab|Biological: Therapeutic Autologous Dendritic Cells	Roswell Park Cancer Institute	Phase 2	
NCT04876248	Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant	Biological: Belantamab Mafodotin|Drug: Lenalidomide	Roswell Park Cancer Institute|GlaxoSmithKline	Phase 2	
NCT05355272	Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)	Drug: Recombinant human growth hormone	Baylor College of Medicine|United States Department of Defense	Phase 2	
NCT06016270	A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer	Drug: hSTC810 400 mg + Paclitaxel|Drug: hSTC810 800 mg + Paclitaxel	STCube, Inc.	Phase 1|Phase 2	

해외 바이오의약품 임상 현황 ('24년 2월 3주)

한국바이오의약품협회, 2024.02.20.

○ 미국 16건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05145816	Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis	Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks)|Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks)|Drug: Belantamab mafodotin 1.4 mg/kg (12 weeks)|Drug: Belantamab mafodotin 1.9 mg/kg (12 weeks)|Drug: Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Drug: Belantamab mafodotin 1.0 mg/kg (12 weeks)	University of Texas Southwestern Medical Center|GlaxoSmithKline	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT05145816
NCT06121843	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	Drug: BMS-986393|Drug: Alnuctamab|Drug: Mezigdomide|Drug: Iberdomide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	https://ClinicalTrials.gov/show/NCT06121843
NCT06071767	Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1	Biological: ChAdOx1.tHIVconsv1|Biological: ChAdOx1.HIVconsv62|Biological: MVA.tHIVconsv3|Biological: MVA.tHIVconsv4|Drug: Vesatolimod (VES)|Drug: GS-5423|Drug: GS-2872|Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)|University of Oxford|Gilead Sciences	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT06071767
NCT06133010	A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients	Biological: mRNA-1647|Biological: Placebo	ModernaTX, Inc.	Phase 2	https://ClinicalTrials.gov/show/NCT06133010
NCT06055608	Advancing Transplantation Outcomes in Children	Drug: Sirolimus|Biological: Belatacept|Drug: Mycophenolate Mofetil|Drug: Tacrolimus (Group1)|Drug: Anti-Thymocyte Globulin (ATG)|Drug: Tacrolimus (Group 2)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://ClinicalTrials.gov/show/NCT06055608

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06255795	The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma	Drug: chidamide, anti-PD1 antibody, and pegaspargase|Drug: DDGP	Ruijin Hospital	Phase 3	https://ClinicalTrials.gov/show/NCT06255795
NCT05910970	Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation	Drug: Adjuvant tislelizumab plus lenvatinib|Drug: Adjuvant tislelizumab	Guangxi Medical University	Phase 3	https://ClinicalTrials.gov/show/NCT05910970
NCT06255262	Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer	Drug: Surufatinib|Drug: Durvalumab	China Medical University, China	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT06255262